CNS disorders therapeutic agent - JCR/Sumitomo Dainippon Pharma

Drug Profile

CNS disorders therapeutic agent - JCR/Sumitomo Dainippon Pharma

Latest Information Update: 05 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator JCR Pharmaceuticals
  • Developer JCR Pharmaceuticals; Sumitomo Dainippon Pharma
  • Class Neuroprotectants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research CNS disorders
  • Discontinued Mental disorders

Most Recent Events

  • 26 Feb 2018 Sumitomo Dainippon Pharma and JCR enter into a license agreement for creation of a Therapeutic agent for CNS disorders
  • 26 Feb 2018 Discontinued for Mental disorders in Japan (IV)
  • 17 Jun 2015 JCR and Sumitomo Dainippon Pharma agree to conduct feasibility study of application of J-Brain Cargo technology to neurological and mental disorder therapeutics in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top